A comparison of match demands using ball-in-play vs. whole match data in elite male youth soccer players

Effective playing time in soccer is typically 90 seconds. This data allows practitioners to gain a deeper understanding of the physical demands imposed on players and plan sessions using targets that better represent match demands

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). A Markov model was developed to assess the cost-effectiveness of rivaroxaban plus ASA vs. ASA alone over a lifetime horizon, from the UK National Health System perspective. METHODS AND RESULTS: The base case analysis assumed that patients entered the model in the event-free health state, with the possibility to experience ≤2 events, transitioning every three-month cycle, through acute and post-acute health states of MI, ischaemic stroke (IS), or intracranial haemorrhage (ICH), and death. Costs, quality-adjusted life-years (QALYs), life years-all discounted at 3.5%-and incremental cost-effectiveness ratios (ICERs) were calculated. Deterministic and probabilistic sensitivity analyses were conducted, as well as scenario analyses. In the model, patients on rivaroxaban plus ASA lived for an average of 14.0 years with no IS/MI/ICH, and gained 9.7 QALYs at a cost of £13 947, while those receiving ASA alone lived for an average of 12.7 years and gained 9.3 QALYs at a cost of £8126. The ICER was £16 360 per QALY. This treatment was cost-effective in 98% of 5000 iterations at a willingness-to-pay threshold of £30 000 per QALY. CONCLUSION: This Markov model suggests that rivaroxaban 2.5 mg bid plus ASA is a cost-effective alternative to ASA alone in patients with chronic CAD or PAD

Origin of the Paleoproterozoic “Giant Quartz Reef” System in the Bundelkhand Craton, India: Constraints from Fluid Inclusion Microthermometry, Raman Spectroscopy, and Geochemical Modelling

AbstractThe Bundelkhand “giant quartz reef” (BGQR) system comprises 20 major quartz reefs which run for tens of km in strike length of average width of 40 m and occurs in spatial intervals of 12–19 km in the Bundelkhand craton, North Central India. The BGQR system is distinct from quartz vein systems originating from crustal scale shearing observed in ancient as well as modern convergent tectonic settings. Fluid inclusions studied in BGQR system are intriguingly diverse although dominated by aqueous fluid which exhibit a broad range of salinity from ~0 to 28.9 wt% NaCl equivalent and temperature of homogenization range of 58 to 385°C. Primary and pseudosecondary aqueous inclusions in assemblages in grain interiors and growth zones vary randomly in their Th—salinity characteristics that preclude identification of discrete fluid events. Aqueous fluid in the BGQR system evolved through mixing of two distinct sources of fluids—a meteoric fluid and a moderate temperature—moderate salinity fluid that was possibly derived from the Bundelkhand granodiorite based on an important clue provided by hydrous mineral bearing fluid inclusions detected by Raman microspectrometry. The results of modeling with PHREEQC indicate that mixing of fluids could be a suitable mechanism in formation of these giant reefs. The available 1-dimensional diffusive transport model for deposition of silica helps in putting constraints on the time span of deposition of silica in the context of the BGQR system. The BGQR system is a possible result of shallow-crustal sources of fluid and silica and could be visualized as a “Paleoproterozoic geothermal system” in a granitic terrane

A comparison of match demands using ball-in-play vs. whole match data in elite male youth soccer players

© 2019 Informa UK Limited, trading as Taylor & Francis Group. Instruction: Effective playing time in soccer is typically 90 seconds.Conclusion: This data allows practitioners to gain a deeper understanding of the physical demands imposed on players and plan sessions using targets that better represent match demands

Little effects of Insulin-like Growth Factor-I on testicular atrophy induced by hypoxia

BACKGROUND: Insulin-like Growth Factor-I (IGF-I) supplementation restores testicular atrophy associated with advanced liver cirrhosis that is a condition of IGF-I deficiency. The aim of this work was to evaluate the effect of IGF-I in rats with ischemia-induced testicular atrophy (AT) without liver disease and consequently with normal serum level of IGF-I. METHODS: Testicular atrophy was induced by epinephrine (1, 2 mg/Kg intra-scrotal injection five times per week) during 11 weeks. Then, rats with testicular atrophy (AT) were divided into two groups (n = 10 each): untreated rats (AT) receiving saline sc, and AT+IGF, which were treated with IGF-I (2 μg.100 g b.w.(-1).day(-1), sc.) for 28d. Healthy controls (CO, n = 10) were studied in parallel. Animals were sacrificed on day 29(th). Hypophyso-gonadal axis, IGF-I and IGFBPs levels, testicular morphometry and histopathology, immuno-histochemical studies and antioxidant enzyme activity phospholipid hydroperoxide glutathione peroxidase (PHGPx) were assessed. RESULTS: Compared to controls, AT rats displayed a reduction in testicular size and weight, with histological testicular atrophy, decreased cellular proliferation and transferrin expression, and all of these alterations were slightly improved by IGF-I at low doses. IGF-I therapy increased signifincantly steroidogenesis and PHGPx activity (p < 0.05). Interestingly, plasma IGF-I did not augment in rats with testicular atrophy treated with IGF-I, while IGFBP3 levels, that reduces IGF-I availability, was increased in this group (p < 0.05). CONCLUSION: In testicular atrophy by hypoxia, condition without IGF-I deficiency, IGF-treatment induces only partial effects. These findings suggest that IGF-I therapy appears as an appropriate treatment in hypogonadism only when this is associated to conditions of IGF-I deficiency (such as Laron Syndrom or liver cirrhosis)